American Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01

A new publication about the discovery and preclinical characterization of OATD-01, authored by the scientists from OncoArendi Therapeutics, has just been accepted by the Journal of Medicinal Chemistry (J. Med. Chem). OATD-01 is a first-in-class chitinase inhibitor, which had recently completed Phase I studies and continues its development as a clinical candidate for the treatment of sarcoidosis, idiopathic pulmonary fibrosis (IPF), and possibly other fibrotic and inflammatory diseases.

The publication describes the drug discovery program that led to the identification of OATD-01. The elements of the medicinal chemistry design, pharmacokinetics and pharmacological properties of the compound are further described in more detail, along with preclinical proof-of-concept data in a model of IPF. These experiments have been performed in-house and by a specialized Japanese CRO.

The Journal of Medicinal Chemistry is undoubtedly one of the top scientific periodicals in the field of small molecule drug discovery. The Drug Annotations series launched by the journal is intended to showcase the most important and highly innovative compounds that have the biggest potential to make a significant impact on the treatment of human diseases. Since the inception of The Drug Annotations Series over 15 years ago, only 55 compounds have received such distinction. Therefore, OncoArendi Therapeutics is very proud that the discovery and development of OATD-01 has been selected by editor Wendy Young, PhD (Senior VP, Small Molecule Drug Discovery, Genentech) to this very prestigious and highly esteemed series of articles.

“This publication is a very important milestone for OncoArendi Therapeutics, which documents not only great science, but above all, great drug discovery work with quality that is on par with leading pharma companies. This publication will make OncoArendi an even more established player in the global biotech scene and strongly mark our leadership position in the field of chitinase inhibitors” – said Dr Rafał Kaminski, Chief Scientific Officer, OncoArendi Therapeutics.

“The data published in this article is a result of several years of hard work and dedication of talented scientists and collaborators of OncoArendi. I would like to thank them all for their passion and efforts, which were recognized by the journal Editors who selected our manuscript for such a high-profile series.” – said Dr Adam Gołebiowski, senior corresponding author and one of the co-founders of OncoArendi Therapeutics.

The research that led to this publication has been co-cofinanced by the National Center for Research and Development (NCBR) in grants, POIR.01.01.01-00-0551/15 (“Development of a first-in-class small molecule drug candidate for treatment of idiopathic pulmonary fibrosis through chitotriosidase inhibition”) and by the National Institutes of Health (NIH) in SBIR grant no 1 R44 HL132721-01 – NHLBI/ NIH (“Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma”).

Publication is now available at: https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01179#

OncoArendi Therapeutics S.A. is an innovative biotech company focused on discovery, development and commercialisation of novel medicines to treat patients with pulmonary diseases and neoplasms. OncoArendi’s business model is based on discovery and development of new therapeutic compounds with the intention to out-license the medicines to pharmaceutical companies. The company develops potential first-in-class or best-in-class medicines for the treatment of diseases associated with unmet medical need. For the development of current research projects OncoArendi Therapeutics has obtained funds from private investors as well as from numerous grants co-financed by national funds, EU funds, Horizon 2020 and the US National Health Institute (NIH) following a competitive procedure. In March 2018 OncoArendi Therapeutics successfully conducted the initial public offering (IPO) which resulted in obtaining 58 million PLN for further development of its biotech projects in the future. The company was first listed on the Warsaw Stock Exchange on 19 April 2018.

For more information visit: https://oncoarendi.com/

Twitter: @oncoarendi

Additional information:

Media contact:

Michał Wierzchowski, cc group

tel. +48 531 613 067

e-mail: michal.wierzchowski@ccgroup.pl

Investor contact:

Katarzyna Mucha, cc group

tel. +48 697 613 712

e-mail: katarzyna.mucha@ccgroup.pl